Avicanna Commercializes ‘Influid’, a Proprietary Water-soluble technology in the Canadian Market
Avicanna Inc. (“Avicanna
” or the
”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN),
a commercial stage, international biopharmaceutical company focused
on the commercialization of evidence-based, cannabinoid-based
products, is pleased to announce the commercialization of
patent-pending, water-soluble technology Influid with an initial
Viola branded beverage infuser SKU for the Canadian market.
Avicanna’s patent-pending, water-soluble
formulation, Influid, utilizes nanotechnology to overcome the
challenges of solubility and absorption of cannabinoids due to
their hydrophobic properties. Developed by Avicanna’s R&D team,
the Self-Nano-Emulsifying Drug Delivery System (“SNEDDS”)
accelerates the overall speed and absorption of cannabinoids
through surface area of contact in the gastrointestinal tract. The
formulation demonstrated cannabinoid shelf-life stability and the
delivery of a consistent concentration with each drop.
“Our research team continues to innovate and
deliver new formulations with consumer experience in mind and we
are excited to progress our proprietary water-soluble technology
from the lab into initial commercial channels. The limitations of
currently available water-soluble formulations are their low drug
loading, poor stability, and the difficulty in masking solubilizer
flavors, whereas the Influid technology addresses all those gaps,”
stated, Dr. Frantz Le Devedec, Executive Vice President of Research
and Product Development.
Product Launch and Commercial
The initial commercialization of the technology
was launched under the Viola brand in Ontario as a Water-Soluble
THC Infuser. It is anticipated to expand across additional province
throughout Canada beginning with New Brunswick as well as medical
channels including the Medical Cannabis by Shoppers online platform
in late Q4 2022. The product has been designed with consideration
for the following benefits:
unscented and can be mixed into any cold or hot beverage of
- Contains 500 mg
of THC per bottle which is equivalent to 50 – 10mg THC
- Packaged into a
portable 20 mL dropper bottle providing easy dosing of 0.5mg of THC
per drop; and
- Serves as a
solution for purchasing and dosing limitations related to THC for
beverages and edibles.
The Influid technology is also available for
commercialization and licensing opportunities through Avicanna’s
international commercial network.
An application for a patent is currently pending
with the United States Patent and Trademark Office (“USPTO”) on the
oral cannabinoid compositions derived from the Influid technology.
Avicanna is currently evaluating in-vivo pharmacokinetic profiles
of its Influid technology in partnership with Dr. Jibran Khokhar at
the University of Guelph.
About Avicanna Inc.
Avicanna is a commercial-stage international
biopharmaceutical company focused on the advancement and
commercialization of evidence-based cannabinoid-based products for
the global medical and pharmaceutical market segments. Avicanna has
an established scientific platform including R&D and clinical
development that has led to the commercialization of more than
thirty products across various market segments:
Medical Cannabis & Wellness
Products: Marketed under the RHO Phyto™ brand these
medical and wellness products are a line of pharmaceutical-grade
cannabinoid products containing varying ratios of cannabidiol
(“CBD”) and tetrahydrocannabinol (“THC”). The product portfolio
contains a full formulary of products including oral, sublingual,
topical, and transdermal deliveries that have controlled dosing,
enhanced absorption and stability studies supported by pre-clinical
data. The formulary is marketed with consumer, patient and
medical-community education and training.
Pipeline: Leveraging Avicanna’s scientific platform,
vertical integration, and real-world evidence, Avicanna has created
a pipeline of patent-pending drug candidates that are
indication-specific and in various stages of clinical development
and commercialization. These cannabinoid-based drug candidates look
to address unmet medical needs in the areas of dermatology, chronic
pain, and various neurological disorders. Avicanna’s first
pharmaceutical preparation (Trunerox™) is in the drug registration
stage in South America.
Click to watch Avicanna’s Corporate Video
SOURCE Avicanna Inc.
For more information about Avicanna, visit
www.avicanna.com, contact Ivana Maric by email at email@example.com
or follow us on social media
on LinkedIn, Twitter, Facebook or Instagram.
The Company posts updates through videos from
the official Company YouTube channel.
Cautionary Note Regarding
Forward-Looking Information and Statements
This news release contains “forward-looking
information” within the meaning of applicable securities laws.
Forward-looking information contained in this news release may be
identified by the use of words such as, “may”, “would”, “could”,
“will”, “likely”, “expect”, “anticipate”, “believe, “intend”,
“plan”, “forecast”, “project”, “estimate”, “outlook” and other
similar expressions. Forward-looking information contained in this
news release includes, without limitation, with respect to the
Company’s future business operations, potential collaborations, the
opinions or beliefs of management and future business goals.
Although the Company believes that the expectations and assumptions
on which such forward looking information is based are reasonable,
undue reliance should not be placed on the forward-looking
information because the Company can give no assurance that they
will prove to be correct. Actual results and developments may
differ materially from those contemplated by these statements.
Forward-looking information is subject to a variety of risks and
uncertainties that could cause actual events or results to differ
materially from those projected in the forward-looking information.
Such risks and uncertainties include, but are not limited to,
current and future market conditions, including the market price of
the common shares of the Company, and the risk factors set out in
the Company’s annual information form dated March 31, 2022, filed
with the Canadian securities regulators and available under the
Company’s profile on SEDAR at www.sedar.com. The statements in this
news release are made as of the date of this release. The Company
disclaims any intent or obligation to update any forward-looking
information, whether as a result of new information, future events
or results or otherwise, other than as required by applicable
A photo accompanying this announcement is available at
Gráfico Histórico do Ativo
De Jan 2023 até Fev 2023
Gráfico Histórico do Ativo
De Fev 2022 até Fev 2023